Revance Therapeutics Inc (NAS:RVNC)
$ 2.85 -0.04 (-1.38%) Market Cap: 297.68 Mil Enterprise Value: 497.95 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics Inc at Stifel Virtual Healthcare Conference Transcript

Nov 17, 2020 / 07:00PM GMT
Release Date Price: $26.41 (-1.09%)
Annabel Samimy
Stifel Nicolaus - Analyst

Hi, good afternoon, everyone, and welcome to the Revance presentation. I am Annabel Samimy, biopharmaceutical analyst here at Stifel. And it's our pleasure to have Mark Foley with us today, CEO of Revance, as well as Toby Schilke, who is somewhere in a box I think on this platform.

So, as we look at Revance today, you are literally jumping into a commercial transition with the launch of your aesthetics platform that includes both fillers and a fintech platform, and you are about to add another with -- I'm going to stay within six months because we're not quite sure. So, why don't I just step back, let you guys have a five minute state of affairs -- brief state of affairs of where Revance is right now and we'll just launch into Q&A.

Mark Foley
Revance Therapeutics, Inc. - President & CEO

Sounds good. Thanks, Annabel. We really appreciate the opportunity to be here. So, I think just stepping back, this has been truly a transformational year for Revance. If you think of where we were this time last year,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot